Sarabjot Pabla: Our latest molecular tumor board with a case of recurrent HCC
Sarabjot Pabla, Head of Clinical and Research Bioinformatics at OmniSeq, shared a post on LinkedIn:
“Another great molecular tumor board is out. I am pleased to be able to contribute to our latest molecular tumor board where our Medical Affairs Team presents a case of recurrent Hepatocellular Carcinoma (HCC) with interesting immune phenotypes discovered on a comprehensive genomic and immune profiling test. I join the team to talk about T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) as a promising target and its mechanism of action for cancer immunotherapy and outlined the prognosis and treatment paradigm of HCC along with discussing the different stages and potential barriers of clinical trial enrollment.”
Source: Sarabjot Pabla/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023